ArticleCurrent microbiology2026
The Effect of Microbiota and Evaluation of Released Cytokines in Schizophrenia Patients.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Bidirectional communication between the gut microbiota and the brain has been increasingly recognized, with growing evidence suggesting its relevance in schizophrenia. Altered microbiota composition may contribute to gastrointestinal barrier disruption, immune activation, and metabolic dysfunction. Given the multifactorial etiology of schizophrenia involving genetic, epigenetic, and environmental factors, microbiota-related mechanisms may represent an important pathway in disease development. This prospective, controlled study investigated gut microbiota composition and systemic inflammatory markers in schizophrenia patients. Blood and stool samples were obtained from 14 patients with schizophrenia and 6 matched healthy controls. Microbiota profiles were determined through 16 S rRNA gene sequencing, while serum levels of Claudin-1, Occludin, E-cadherin, Zonulin, IL-1β, IL-6, and TNF-α were analyzed using ELISA. Firmicutes and Bacteroidota were the predominant phyla in both groups. However, alpha diversity (Shannon index, p < 0.05) and beta diversity (Permanova, p < 0.01) analyses showed significant differences between patients and controls. ELISA results demonstrated significantly elevated levels of IL-1β, IL-6, TNF-α, Claudin-1, and E-cadherin (all p < 0.05) in patients, whereas Occludin was significantly decreased (p < 0.05) and Zonulin levels were unexpectedly lower compared to controls. Results indicate significant gut dysbiosis and heightened systemic inflammation in schizophrenia patients. This interplay between microbial composition, intestinal permeability, and inflammatory processes may contribute to the pathophysiology of the disorder. Further studies with larger cohorts, including antipsychotic-naïve first-episode patients, are warranted to clarify causality and evaluate microbiota-targeted interventions as potential therapeutic strategies.
Indexed as
Identifiers
42509400What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.